Loomis Sayles & Co. L P Boosts Stock Position in Avantor, Inc. (NYSE:AVTR)

Loomis Sayles & Co. L P raised its position in Avantor, Inc. (NYSE:AVTR) by 1.4% during the third quarter, Holdings Channel.com reports. The firm owned 749,713 shares of the company’s stock after buying an additional 10,564 shares during the period. Loomis Sayles & Co. L P’s holdings in Avantor were worth $19,395,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of AVTR. Intech Investment Management LLC lifted its stake in shares of Avantor by 1.8% during the second quarter. Intech Investment Management LLC now owns 29,068 shares of the company’s stock valued at $616,000 after buying an additional 514 shares during the period. Arizona State Retirement System lifted its stake in shares of Avantor by 0.3% during the 2nd quarter. Arizona State Retirement System now owns 186,567 shares of the company’s stock worth $3,955,000 after purchasing an additional 528 shares during the period. Veracity Capital LLC lifted its stake in shares of Avantor by 1.0% during the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after purchasing an additional 543 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Avantor by 2.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock worth $571,000 after purchasing an additional 733 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of Avantor by 6.2% in the third quarter. US Bancorp DE now owns 12,615 shares of the company’s stock valued at $326,000 after purchasing an additional 734 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Price Performance

AVTR stock opened at $21.01 on Wednesday. The firm has a market cap of $14.30 billion, a P/E ratio of 45.67, a price-to-earnings-growth ratio of 2.52 and a beta of 1.35. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor, Inc. has a 1 year low of $19.59 and a 1 year high of $28.00. The stock has a 50-day simple moving average of $23.65 and a 200-day simple moving average of $23.79.

Insiders Place Their Bets

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares in the company, valued at $740,372.64. The trade was a 10.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on AVTR shares. Wells Fargo & Company reduced their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Robert W. Baird cut their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. UBS Group lowered their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Finally, Barclays decreased their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.57.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.